In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
12 authors at 4 institutions in 2 countries.
Moriah R ArnoldMedical Scientist Training Program, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0002-5916-7978 Gabriel M CohnDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-5901-2506 Kezia Catharina OxeDanish Cancer Institute, Nucleolar Stress and Disease Group, Strandboulevarden 49, 2100 Copenhagen, Denmark.ORCID 0000-0002-4921-4750 Somarr N ElliottDepartment of Neurology and Jungers Center for Neurosciences Research, Oregon Health and Science University, Portland, OR, USA.ORCID 0009-0002-4347-9923 Cynthia MooreResearch Services, Neurocytology Laboratory, Veterans Affairs Medical Center, Portland, OR, USA.ORCID 0000-0002-9852-8748 Sahar ShekoohiDepartment of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.ORCID 0009-0007-4545-4523 Dillon BrownellDepartment of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA.ORCID 0009-0005-2432-1460 Charles K MeshulResearch Services, Neurocytology Laboratory, Veterans Affairs Medical Center, Portland, OR, USA.ORCID 0000-0002-3908-0795 Stephan N WittDepartment of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.ORCID 0000-0002-6462-2840 Dorthe H LarsenDanish Cancer Institute, Nucleolar Stress and Disease Group, Strandboulevarden 49, 2100 Copenhagen, Denmark.ORCID 0000-0002-8280-1252 Vivek K UnniDepartment of Neurology and Jungers Center for Neurosciences Research, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-8833-6542 Oregon Health & Science University · USDanish Cancer Society · DKLouisiana State University Health Sciences Center Shreveport · USVeterans Health Administration · US
Funding
Ultrastructure and Single Particle Microscopy CoreP30NS061800 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI AICHER, SUE A · 2009 to 2020
$6.6MCHRONIC MYELOGENOUS LEUKEMIA AND BCR-ABL SUBSTRATESR01CA065823 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J · 1995 to 2021
$4.7MMechanisms of Neurodegeneration in Lewy Body DisordersR01NS102227 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI UNNI, VIVEK · 2017 to 2021
$1.9MChronic Myelogenous Leukemia and BCR-ABL SubstratesR37CA065823 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J · 2011 to 2015
$1.5MThe role of alpha-synuclein in nucleolar DNA double-strand break repair and cellular senescenceF30AG082406 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Moriah Rebecca Arnold · 2023 to 2026
$216kNCI NIH HHS R01 CA065823NCI NIH HHS R37 CA065823NIA NIH HHS F30 AG082406NINDS NIH HHS P30 NS061800NINDS NIH HHS R01 NS102227
6 · The paper itselfAbstract
Although an increased risk of the skin cancer melanoma in people with Parkinson's Disease (PD) has been shown in multiple studies, the mechanisms involved are poorly understood, but increased expression of the PD-associated protein alpha-synuclein (αSyn) in melanoma cells may be important. Our previous work suggests that αSyn can facilitate DNA double-strand break (DSB) repair, promoting genomic stability. We now show that αSyn is preferentially enriched within the nucleolus in the SK-MEL28 melanoma cell line, where it colocalizes with DNA damage markers and DSBs. Inducing DSBs specifically within nucleolar ribosomal DNA (rDNA) increases αSyn levels near sites of damage. αSyn knockout increases DNA damage within the nucleolus at baseline, after specific rDNA DSB induction, and prolongs the rate of recovery from this induced damage. αSyn is important downstream of ATM signaling to facilitate 53BP1 recruitment to DSBs, reducing micronuclei formation and promoting cellular proliferation, migration, and invasion.
Identifiers
PMID38260370
PMCPMC10802588
OpenAlexW4390858152
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390